Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to demonstrate that ArTiMist (sublingual artemether spray) is better than intravenous quinine in reducing parasite counts by >= 90% within 24 hours after the start of treatment in children with severe malaria, or uncomplicated malaria with gastrointestinal complications
Malaria causes significant morbidity and mortality in children in developing countries, despite the availability of highly effective antimalarial therapy. One of the key contributing factors is the delay in the initiation of treatment.
ArTiMist is a sublingual formulation of the established antimalarial treatment, artemether. In previous studies good bioavailability has been demonstrated. In an exploratory study (ART003) ArTiMist demonstrated a non statistically significant improvement of 26% (when compared to intravenous quinine) in the numbers of patients experiencing a parasite reduction of >= 90% within 24 hours of the initiation of treatment.
This Phase 3 study is being conducted to establish whether treatment with ArTiMist in children with severe falciparum malaria or uncomplicated falciparum malaria with gastrointestinal complications is at least 20% superior in providing parasitological success (defined as >= 90% reduction in parasite count at 24 hours after start of treatment) when compared to intravenous quinine.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ArTiMist | Experimental |
| |
| Quinine | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Artemether Sublingual Spray | Drug | Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints |
|
| Measure | Description | Time Frame |
|---|---|---|
| Parasitological Success (MITT) | Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose | 24 hours after start of treatment |
| Parasitological Success (PP) | Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose | 24 hours after start of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Parasite Clearance Time (PCT) [MITT Population] | Parasite clearance time (PCT). Time in hours from the initiation of therapy until the first of two successive parasite negative smears (zero parasite counts) are obtained | 28 days after start of treatment |
| PCT 90 [MITT Population] |
Not provided
Inclusion Criteria:
The patient's legally acceptable representative has provided informed consent and the patient has assented (where relevant) to participation in the trial
The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive
The patient has falciparum malaria as evidenced by thick or thin blood smears of ≥ 500 P Falciparum per mcl (patients with mixed infections may be included provided ≥ 500 P Falciparum per mcl)
The patient has either:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Daryl Bendel, MBChB MFPM | Xidea Solutions Limited | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre National de Recherche et de Formation sur le Paludisme (CNRFP) | Ouagadougou | 01 BP 2208 | Burkina Faso | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26303805 | Derived | Bendel D, Rulisa S, Ansah P, Sirima S. Efficacy of a novel sublingual spray formulation of artemether in African children with Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2015 Nov;59(11):6930-8. doi: 10.1128/AAC.00243-15. Epub 2015 Aug 24. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | ArTiMist | Doses of 3 mg/kg were administered sublingually at: 0 h, 8 h, 24 h, 36 h, 48 h, and 60 h. Following the initial six doses, subjects could, at the discretion of the Investigator receive a further four daily doses of 3 mg/kg ArTiMistâ„¢ to complete a seven day treatment course, or be converted to another suitable treatment or a suitable course of combination therapy in accordance with national drugs policy where applicable. |
| FG001 | Quinine | A loading dose of 20 mg/kg was given over four hours and thereafter 10 mg/kg was given every eight hours until the subject was able to swallow. Thereafter, patients were given quinine syrup or crushed tablets (10 mg/kg every eight hours) or another suitable treatment to ensure they received at least seven days of therapy, or be converted to another suitable treatment or a suitable course of combination therapy, in accordance with national drugs policy where applicable. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | ArTiMist | Doses of 3 mg/kg were administered sublingually at: 0 h, 8 h, 24 h, 36 h, 48 h, and 60 h. Following the initial six doses, subjects could, at the discretion of the Investigator receive a further four daily doses of 3 mg/kg ArTiMistâ„¢ to complete a seven day treatment course, or be converted to another suitable treatment or a suitable course of combination therapy in accordance with national drugs policy where applicable. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Parasitological Success (MITT) | Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose | The Modified Intention to Treat (MITT) population included all randomised subjects who received at least one dose of study medication and had evaluable parasite counts at 24 hours after first dosing. 7 subjects for ArTiMist and 3 subjects for quinine were excluded due to no baseline or 24 h parasite count | Posted | Number | participants | 24 hours after start of treatment |
|
Adverse events were reported from the time of signing informed consent until the final study visit. Adverse events that started or worsened after start of treatment were considered Treatment Emergent.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | ArTiMist |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 14.0 | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 14.0 | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr Daryl Bendel | Xidea Solutions Limited | daryl@xideasolutions.com |
Not provided
| ID | Term |
|---|---|
| D016778 | Malaria, Falciparum |
| D008288 | Malaria |
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| ID | Term |
|---|---|
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
| D000079426 | Vector Borne Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011803 | Quinine |
| ID | Term |
|---|---|
| D002930 | Cinchona Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011812 | Quinuclidines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Quinine | Drug | Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours |
|
Time for parasite counts to fall by 90% |
| 28 days after start of treatment |
| PCT 50 [MITT Population] | Time for parasite counts to fall by 50% | 28 days after start of treatment |
| PRR 24 [MITT Population] | The percentage reduction in parasite counts 24 hours after first dose | 28 days after start of treatment |
| PRR 12 [MITT Population] | The percentage reduction in parasite counts 12 hours after first dose | 28 days after start of treatment |
| Fever Clearance Time (FCT) | Time in hours from the initiation of therapy until the disappearance of fever (tympanic temperature < 38.0) that lasted at least 24 hours. | 28 days after start of treatment |
| Complete Cure Rate | The complete resolution of clinical signs and symptoms, malaria-related laboratory abnormalities, and elimination of asexual parasites by Day 7, with no recurrence up to Day 28 (+/- 2 days), and the 48h parasite count to be < 25% of baseline with no clinical deterioration | 28 days after the start of treatment |
| Early Treatment Failure | Early treatment failure is indicated by one or more of the following:
| Three days after the start of treatment |
| Late Clinical Failure |
| 28 days after the start of treatment |
| Late Parasitological Failure | o Parasitaemia on any day from Day 7 to Day 28 and tympanic temperature ≤ 38.0°C | 28 days after the start of treatment |
| Time to Return to Full Consciousness | Time in hours to return to full consciousness (Blantyre Coma Scale = 5), if level of consciousness is reduced (Blantyre Coma Scale <5) prior to dosing or within 24hours of first dosing. For the Blantyre Coma Scale Total - maximum 5, eye movement - maximum 1, best motor response - maximum 2, best verbal response - maximum 2 | 28 days after start of treatment |
| Time to Return to Normal Per os Status | Time in hours to return to normal per os status. Normal per os was when the investigator considered the patient to be able to eat and drink normally. | 28 days after start of treatment |
| Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities | 28 days after start of treatment |
| Number of Deaths or Neurological Sequelae at Day 28 | 28 days after start of treatment |
| Navrongo Health Research Centre |
| Navrongo |
| Navrongo |
| P.O. Box 114 |
| Ghana |
| Rwinkwavu District Hospital | Rwinkwavu | Eastern Province | Rwanda |
| BG001 | Quinine | A loading dose of 20 mg/kg was given over four hours and thereafter 10 mg/kg was given every eight hours until the subject was able to swallow. Thereafter, patients were given quinine syrup or crushed tablets (10 mg/kg every eight hours) or another suitable treatment to ensure they received at least seven days of therapy, or be converted to another suitable treatment or a suitable course of combination therapy, in accordance with national drugs policy where applicable |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Disease Definition - Severe or complicated malaria | Number | participants |
|
| Weight | Mean | Standard Deviation | kg |
|
| Pulse rate | Mean | Standard Deviation | bpm |
|
| Tympanic Temperature | Mean | Standard Deviation | Degrees Centigrade |
|
| Respiratory Rate | Mean | Standard Deviation | breaths/min |
|
| Blantyre Coma Scale | Blantyre Coma scale scores out of 5, full consciousness, by adding the scores of the following 3 domains. Any score ≤ 4 is considered abnormal, Eye Movement 1 Watches or follows 0 Fails to watch or follow Best Motor Response 2 Localizes painful stimulus 1 Withdraws limb from painful stimulus 0 No response or inappropriate response Best Verbal Response 2 Cries appropriately with pain, or if verbal, speaks 1 Moan or abnormal cry with pain 0 No vocal response with pain | Number | participants |
|
| Parasite Counts | Mean | Standard Deviation | p falciparum /mcl |
|
| Parasite Count (median) | Median | Full Range | p falciparum /mcl |
|
| Units | Counts |
|---|
| Participants |
|
|
|
| Secondary | Parasite Clearance Time (PCT) [MITT Population] | Parasite clearance time (PCT). Time in hours from the initiation of therapy until the first of two successive parasite negative smears (zero parasite counts) are obtained | Posted | Mean | Standard Deviation | hours | 28 days after start of treatment |
|
|
|
|
| Secondary | PCT 90 [MITT Population] | Time for parasite counts to fall by 90% | Posted | Mean | Standard Deviation | hours | 28 days after start of treatment |
|
|
|
|
| Secondary | PCT 50 [MITT Population] | Time for parasite counts to fall by 50% | Posted | Mean | Standard Deviation | hours | 28 days after start of treatment |
|
|
|
|
| Secondary | PRR 24 [MITT Population] | The percentage reduction in parasite counts 24 hours after first dose | Posted | Mean | Standard Deviation | percentage of baseline | 28 days after start of treatment |
|
|
|
|
| Secondary | PRR 12 [MITT Population] | The percentage reduction in parasite counts 12 hours after first dose | Posted | Mean | Standard Deviation | percentage of baseline | 28 days after start of treatment |
|
|
|
|
| Secondary | Fever Clearance Time (FCT) | Time in hours from the initiation of therapy until the disappearance of fever (tympanic temperature < 38.0) that lasted at least 24 hours. | Posted | Mean | Standard Deviation | hours | 28 days after start of treatment |
|
|
|
|
| Secondary | Complete Cure Rate | The complete resolution of clinical signs and symptoms, malaria-related laboratory abnormalities, and elimination of asexual parasites by Day 7, with no recurrence up to Day 28 (+/- 2 days), and the 48h parasite count to be < 25% of baseline with no clinical deterioration | For some subjects, this endpoint was not evaluable and/or not all data was received. | Posted | Number | participants | 28 days after the start of treatment |
|
|
|
|
| Secondary | Early Treatment Failure | Early treatment failure is indicated by one or more of the following:
| Posted | Number | participants | Three days after the start of treatment |
|
|
|
| Secondary | Late Clinical Failure |
| Posted | Number | participants | 28 days after the start of treatment |
|
|
|
| Primary | Parasitological Success (PP) | Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose | The Per Protocol (PP) population included the subjects in the MITT population who had received at least 80% of doses up to the time of discharge from the hospital, had evaluable data up to and including Day 28 and had no major protocol violations. | Posted | Number | participants | 24 hours after start of treatment |
|
|
|
|
| Secondary | Late Parasitological Failure | o Parasitaemia on any day from Day 7 to Day 28 and tympanic temperature ≤ 38.0°C | Posted | Number | participants | 28 days after the start of treatment |
|
|
|
| Secondary | Time to Return to Full Consciousness | Time in hours to return to full consciousness (Blantyre Coma Scale = 5), if level of consciousness is reduced (Blantyre Coma Scale <5) prior to dosing or within 24hours of first dosing. For the Blantyre Coma Scale Total - maximum 5, eye movement - maximum 1, best motor response - maximum 2, best verbal response - maximum 2 | Posted | Mean | Standard Deviation | hours | 28 days after start of treatment |
|
|
|
| Secondary | Time to Return to Normal Per os Status | Time in hours to return to normal per os status. Normal per os was when the investigator considered the patient to be able to eat and drink normally. | Posted | Mean | Standard Deviation | hours | 28 days after start of treatment |
|
|
|
| Secondary | Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities | Posted | Number | participants | 28 days after start of treatment |
|
|
|
| Secondary | Number of Deaths or Neurological Sequelae at Day 28 | Posted | Number | participants | 28 days after start of treatment |
|
|
|
| 4 |
| 77 |
| 43 |
| 77 |
| EG001 | Quinine | 10 | 74 | 44 | 74 |
| Bronchopneumonia | Infections and infestations | MedDRA 14.0 | Non-systematic Assessment |
|
| Cerebral Malaria | Infections and infestations | MedDRA 14.0 | Non-systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA 14.0 | Non-systematic Assessment |
|
| Malaria | Infections and infestations | MedDRA 14.0 | Non-systematic Assessment |
|
| Sepsis | Infections and infestations | MedDRA 14.0 | Non-systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | MedDRA 14.0 | Non-systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 14.0 | Non-systematic Assessment |
|
| Pyrexia | General disorders | MedDRA 14.0 | Non-systematic Assessment |
|
| Malaria | Infections and infestations | MedDRA 14.0 | Non-systematic Assessment |
|
| Respiratory Tract Infection | Infections and infestations | MedDRA 14.0 | Non-systematic Assessment |
|
| Proteinuria | Renal and urinary disorders | MedDRA 14.0 | Non-systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 14.0 | Non-systematic Assessment |
|
| Bronchitis | Respiratory, thoracic and mediastinal disorders | MedDRA 14.0 | Non-systematic Assessment |
|
Not provided
Not provided
| D006572 |
| Heterocyclic Compounds, Bridged-Ring |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |